Skip to main content
. 2023 Jul 27;13:12176. doi: 10.1038/s41598-023-38837-9

Table 3.

Plasma lipid profile (mg/dL) and atherogenic indices (TC/HDL-C and Non HDL-C) of the different sub-groups.

Group TC HDL-C TC/HDL-C Non HDL-C LDL-C TG
NC 84.38a ± 1.74 46.75a ± 1.82 1.83a ± 0.1 37.63a ± 2.83 19.8 a ± 2.9 89.0a ± 2.10
MC 307.50b ± 11.40 39.40b ± 1.27 7.84b ± 0.3 268.1b ± 10.9 236.4 b ± 9.9 158.5b ± 6.50
A 197.80c ± 6.14 43.25a ± 1.31 4.58c ± 0.2 154.1c ± 5.7 131.9 c ± 5.8 110.7c ± 4.60
N1 259.80d ± 6.00 38.40b ± 1.29 6.84d ± 0.3 221.4d ± 6.6 197.4 d ± 5.8 120.1d ± 5.04
NN1 267.50d ± 6.53 40.50b ± 1.05 6.63d ± 0.2 227d ± 6.5 201.8 d ± 6.5 125.6d ± 2.50
N2 277.50e ± 5.05 40.40b ± 1.28 6.93d ± 0.3 237.1d ± 5.4 210.5 d ± 5.4 133.2df ± 1.98
NN2 275.30d ± 6.20 40.60b ± 0.5 6.8d ± 0.2 234.6d ± 6.4 207.1d ± 6.2 137.4f ± 2.00
AN1 122.00f ± 2.58 47.25a ± 1.63 2.61e ± 0.1 74.75e ± 2.99 53.9e ± 3.4 104.1ce ± 3.50
ANN1 123.60f ± 2.80 45.25a ± 0.77 2.7eg ± 0.1 78.38e ± 3.54 58.6 e ± 3.7 98.75ae ± 3.04
AN2 148.50g ± 3.60 46.75a ± 1.39 3.2fg ± 0.1 101.8f ± 3.4 80.3f ± 3.8 107.2ce ± 4.30
ANN2 155.60g ± 3.10 46.00a ± 1.16 3.4f ± 0.1 109.6f ± 3.6 87.7f ± 3.1 109.8ce ± 3.80

Values are expressed as means ± SE (n = 8). Significance was considered at p < 0.05 within columns where different letters indicate statistical significance.

.NC control normal, MC metabolic syndrome control, A rats given atorvastatin drug, N1 rats received nutraceutical 1, NN1 rats treated with nutraceutical 1nanostructure, N2 rats received nutraceutical 2, NN2 rats given nutraceutical 2 nanostructure, AN1 rats taken atorvastatin drug with nutraceutical 1, ANN1 rats given atorvastatin drug with nutraceutical 1 nanostructure, AN2 rats treated with atorvastatin drug with nutraceutical 2, ANN2 rats received atorvastatin drug with nutraceutical 2 nanostructure, TC total cholesterol, TG triglycerides, HDL-C high density lipoprotein-cholesterol, LDL-C low density lipoprotein-cholesterol.

HHS Vulnerability Disclosure